<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg"/></p>
<p>RP-3467 是一種強效的小分子 Polθ 抑制劑，屬於與 BRCA 突變和其他基因組改變相關的合成致死靶點。來源：PeopleImages/Shutterstock.com。</p>
<p>吉利德科學已簽署協議收購 Repare Therapeutics 的聚合酶 theta (Polθ) ATP 酶抑制劑 RP-3467。</p>
<p>該交易涉及對 Repare 的總對價高達 3000 萬美元，並直接影響公司的現金狀況和即將進行的股東安排。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Repare Therapeutics Inc 的 RP-6306</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Replimune Ltd 的 Vusolimogene Oderparepvec</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現有效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>根據條款，吉利德將向 Repare 支付 2500 萬美元的預付款，受制於常規的扣留和調整，並在完成某些技術轉讓活動後再支付最多 500 萬美元。</p>
<p>在 2025 年 11 月 14 日，Repare 宣佈與 XenoTherapeutics 和 Xeno Acquisition 簽署了最終安排協議。根據該協議，Xeno 同意購買 Repare 所有已發行和流通的普通股。</p>
<p>每位股東每股將收到的現金金額將基於 Repare 的結算現金餘額，扣除與交易相關的費用和未償債務後計算。</p>
<p>Polθ ATP 酶抑制劑收購的預付款增加了 Repare 的現金儲備，從而提高了對股東支付的估計。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>根據修訂後的現金餘額，Repare 估計股東在交易完成時將獲得約 2.20 美元的普通股每股收益。</p>
<p>Repare Therapeutics 總裁、首席執行官兼首席財務官 Steve Forte 表示：“我們很高興宣佈這一交易，它將吉利德在腫瘤研究和開發方面的領先專業知識與 RP-3467 這一潛在的最佳 Polθ ATP 酶抑制劑結合在一起。這是 Repare 今年第三筆也是最重要的投資組合交易。”</p>
<p>RP-3467 是一種強效的小分子 Polθ 抑制劑，屬於與乳腺癌基因 (BRCA) 突變和其他基因組改變相關的合成致死靶點。</p>
<p>在 2025 年 5 月，Repare 與加拿大生物技術公司 DCx Biotherapeutics 簽署了發現平台和知識產權 (IP) 的外部許可協議。</p>
<h2>製藥技術卓越獎 - 提名已關閉</h2>
<p>製藥技術卓越獎 的提名現已關閉。感謝所有參與的組織 - 你們的響應非常出色，展示了卓越的創新、領導力和影響力。</p>
<p><strong>行動中的卓越</strong></p>
<p>因在 綜合製造 方面的業務擴展而獲得 2025 年製藥技術卓越獎的 Upperton Pharma Solutions 正在快速擴展其在英國的 GMP 和無菌製造能力。瞭解 Upperton 的綜合 CDMO 模型如何幫助製藥公司從早期開發階段過渡到臨牀和小眾商業供應，減少交接和加快時間表。</p>
<p>發現影響</p>

RPTX

吉利德科學

<p>吉利德科學已同意收購 Repare Therapeutics 的 Polθ ATP 酶抑制劑 RP-3467，交易金額最高可達 3000 萬美元。該交易包括 2500 萬美元的預付款，以及在技術轉讓完成後最高可達 500 萬美元的付款。這項收購增強了 Repare 的現金儲備，影響了股東的分紅，預計為每股 2.20 美元。Repare 的首席執行官 Steve Forte 強調此次交易是一個重要的投資組合舉措，將吉利德在腫瘤學領域的專業知識與 RP-3467 在靶向 BRCA 突變方面的潛力相結合</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg"/></p>
<p>RP-3467 is a potent small molecule inhibitor of Polθ, a synthetic lethality target linked to BRCA mutations and other genomic alterations. Credit: PeopleImages/Shutterstock.com.</p>
<div class="lb-trans"><p>RP-3467 是一種強效的小分子 Polθ 抑制劑，屬於與 BRCA 突變和其他基因組改變相關的合成致死靶點。來源：PeopleImages/Shutterstock.com。</p>
</div><p>Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.</p>
<div class="lb-trans"><p>吉利德科學已簽署協議收購 Repare Therapeutics 的聚合酶 theta (Polθ) ATP 酶抑制劑 RP-3467。</p>
</div><p>The transaction involves a total consideration of up to $30m to Repare and directly influences the company’s cash status and upcoming shareholder arrangements.</p>
<div class="lb-trans"><p>該交易涉及對 Repare 的總對價高達 3000 萬美元，並直接影響公司的現金狀況和即將進行的股東安排。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Repare Therapeutics Inc's RP-6306</h4>
<div class="lb-trans"><h4>NPVM: Repare Therapeutics Inc 的 RP-6306</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Replimune Ltd's Vusolimogene Oderparepvec</h4>
<div class="lb-trans"><h4>NPVM: Replimune Ltd 的 Vusolimogene Oderparepvec</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現有效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>According to the terms, Gilead will pay Repare $25m upfront, subject to customary holdbacks and adjustments, and up to an additional $5m upon completion of certain technology transfer activities.</p>
<div class="lb-trans"><p>根據條款，吉利德將向 Repare 支付 2500 萬美元的預付款，受制於常規的扣留和調整，並在完成某些技術轉讓活動後再支付最多 500 萬美元。</p>
</div><p>On 14 November 2025, Repare announced a definitive arrangement agreement with XenoTherapeutics and Xeno Acquisition. Under this agreement, Xeno agreed to purchase all of Repare’s issued and outstanding common shares.</p>
<div class="lb-trans"><p>在 2025 年 11 月 14 日，Repare 宣佈與 XenoTherapeutics 和 Xeno Acquisition 簽署了最終安排協議。根據該協議，Xeno 同意購買 Repare 所有已發行和流通的普通股。</p>
</div><p>The amount of cash each shareholder will receive per share will be based on Repare’s closing cash balance, after subtracting transaction-related expenses and outstanding liabilities.</p>
<div class="lb-trans"><p>每位股東每股將收到的現金金額將基於 Repare 的結算現金餘額，扣除與交易相關的費用和未償債務後計算。</p>
</div><p>The upfront payment from the Polθ ATPase inhibitor acquisition has increased Repare’s cash reserves, thereby raising the estimate for shareholder payments.</p>
<div class="lb-trans"><p>Polθ ATP 酶抑制劑收購的預付款增加了 Repare 的現金儲備，從而提高了對股東支付的估計。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>Based on the revised cash balance, Repare estimates shareholders will receive about $2.20 per common share upon closing the arrangement transaction.</p>
<div class="lb-trans"><p>根據修訂後的現金餘額，Repare 估計股東在交易完成時將獲得約 2.20 美元的普通股每股收益。</p>
</div><p>Repare Therapeutics president, CEO and chief financial officer Steve Forte said: “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor. This marks the third and most significant portfolio transaction for Repare this year.”</p>
<div class="lb-trans"><p>Repare Therapeutics 總裁、首席執行官兼首席財務官 Steve Forte 表示：“我們很高興宣佈這一交易，它將吉利德在腫瘤研究和開發方面的領先專業知識與 RP-3467 這一潛在的最佳 Polθ ATP 酶抑制劑結合在一起。這是 Repare 今年第三筆也是最重要的投資組合交易。”</p>
</div><p>RP-3467 is a potent small molecule inhibitor of Polθ, a synthetic lethality target linked to breast cancer gene (BRCA) mutations and other genomic alterations.</p>
<div class="lb-trans"><p>RP-3467 是一種強效的小分子 Polθ 抑制劑，屬於與乳腺癌基因 (BRCA) 突變和其他基因組改變相關的合成致死靶點。</p>
</div><p>In May 2025, Repare entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP).</p>
<div class="lb-trans"><p>在 2025 年 5 月，Repare 與加拿大生物技術公司 DCx Biotherapeutics 簽署了發現平台和知識產權 (IP) 的外部許可協議。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 提名已關閉</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>製藥技術卓越獎 的提名現已關閉。感謝所有參與的組織 - 你們的響應非常出色，展示了卓越的創新、領導力和影響力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行動中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>因在 綜合製造 方面的業務擴展而獲得 2025 年製藥技術卓越獎的 Upperton Pharma Solutions 正在快速擴展其在英國的 GMP 和無菌製造能力。瞭解 Upperton 的綜合 CDMO 模型如何幫助製藥公司從早期開發階段過渡到臨牀和小眾商業供應，減少交接和加快時間表。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>發現影響</p>
</div>

吉利德科學將收購 Repare Therapeutics 的 RP-3467